Date: 2013-09-03
Type of information: Licensing agreement
Compound: CompoZr ® zinc finger nuclease (ZFN) technology
Company: Horizon Discovery (UK) Sigma-Aldrich (USA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On September 3, 2013, Horizon Discovery, a UK provider of research tools to support the development of personalized medicines, has announced it has entered into a non-exclusive license agreement with Sigma-Aldrich (Sigma) for use of their CompoZr ® zinc finger nuclease (ZFN) technology. The deal gives Horizon the commercial freedom to apply the technology alongside its proprietary rAAV technology in its gene-editing service and cell line product business units. Horizon will immediately begin using ZFN technology as part of its unique custom cell line generation service, where both ZFN and rAAV technologies will be applied, either independently or in combination, to deliver the full spectrum of genomic modifications as efficiently and cost-effectively as possible. The offering will be marketed under Horizon’s precision gene-editing brand GENESIS™. Under the terms of the deal, Horizon will obtain ZFNs manufactured by Sigma for use in commercial development of cell based products and to provide commercial gene editing services.
Financial terms: Financial terms were not disclosed.
Latest news:
